Last quarter (Q3 2023), Sio Gene Therapies's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Sio Gene Therapies's net income was $4.02M. See Sio Gene Therapies’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
Total Revenue	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 20.40M	$ 71.56M	$ 42.20M	$ 69.17M	$ 127.02M	$ 213.32M
Operating Income	$ -20.40M	$ -71.56M	$ -42.20M	$ -69.17M	$ -127.02M	$ -213.32M
Net Non Operating Interest Income Expense	$ -8.00K	$ -27.00K	$ -799.00K	$ -4.38M	$ -7.53M	$ -7.54M
Other Income Expense	$ 832.00K	$ 39.00K	$ 10.36M	$ 1.36M	$ 5.62M	$ 211.00K
Pretax Income	$ -20.51M	$ -71.63M	$ -32.64M	$ -72.19M	$ -128.93M	$ -220.65M
Tax Provision	$ 283.00K	$ 259.00K	$ -212.00K	$ 438.00K	$ 133.00K	$ 921.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -20.79M	$ -71.89M	$ -32.42M	$ -72.63M	$ -129.06M	$ -221.57M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 20.40M	$ 71.56M	$ 42.20M	$ 69.17M	$ 127.02M	$ 213.32M
Net Income From Continuing And Discontinued Operation	$ -28.83M	$ -71.90M	$ -32.42M	$ -72.63M	$ -129.06M	$ -221.57M
Normalized Income	$ -24.81M	-	$ -32.42M	$ -72.63M	$ -129.06M	$ -221.57M
Interest Expense	$ 8.00K	-	$ 799.00K	$ 4.38M	$ 7.53M	$ 7.54M
EBIT	$ -24.84M	-	$ -31.84M	$ -67.81M	$ -121.40M	$ -213.11M
EBITDA	$ -24.32M	-	$ -29.37M	$ -64.72M	$ -118.95M	$ -210.02M

Currency in USD

Sio Gene Therapies Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing